Navigation Links
AbbeyMoor Medical Receives FDA Approval for Design Improvements to The Spanner(TM) Prostatic Stent
Date:7/6/2009

PARKERS PRAIRIE, Minn., July 6 /PRNewswire/ -- AbbeyMoor Medical Inc., a developer and manufacturer of medical devices for the management and treatment of prostatic obstruction, announced today that it has received PMA approval from the US Food and Drug Administration (FDA) for design changes to their flagship product, The Spanner(TM) Prostatic Stent.

"These changes are aimed at further improving patient comfort over the current highly accepted levels," said Darren Cook, director of marketing with the company. "Our goal is to hear an even greater percentage of our patient's state that they are not aware of the device's presence." According to Mark Whalen, VP of product development with the company, "The approved changes to the device result in a significant increase in flexibility over the current Spanner design with no impact to the ease of delivery and removal of the device."

The Spanner is a temporary prostatic stent designed to aid men who are experiencing difficulty in urination due to prostatic obstruction. Device placement can be performed in a physician office and does not require cystoscopy or anesthesia for placement. The Spanner is an alternative to indwelling catheterization, intermittent catheterization, or the use of a suprapubic tube in some patients.

About AbbeyMoor Medical

AbbeyMoor Medical is a privately held company that develops innovative medical devices focused on the management and treatment of male voiding dysfunction. The company's initial focus is on the development and commercialization of The Spanner.

For more information, please visit www.thespanner.com


'/>"/>
SOURCE AbbeyMoor Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Dr. John Mach Appointed Chief Medical Officer at XLHealth
2. General Dynamics Awarded $9 Million Contract for U.S. Army Medical Command Lean Six Sigma Support
3. Health Integrated Hosts Industry Collaborative Focused on the Patient-Centered Medical Home (PCMH)
4. ATS Medical Announces FDA Clearance and First Implant of New ATS Simulus Semi-Rigid Annuloplasty Band
5. GoldenAgeMedical.Com Announces National TV Campaign
6. NEJM study addresses impact of Medicare Part D on medical spending
7. Scienceroll.com on the Medical Implications of Virtual Worlds
8. Patients Suffering from Diabetes Now Have the Option to Suffer No More with Diabetic Free All Natural Medical Herbal Extracts Capsules
9. American Society of Medical Doctors Established to Protect the Bond Between Physicians and Patients; Organizing Doctors to Oppose Government-Run Health Care
10. Successful Beginning for Wellstone Muscular Dystrophy Center at Boston Biomedical Research Institute
11. Winner Medical Signs PurCotton Sales Agreement With Consumer Products Leader in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to create ... it streamlines the reporting process and provides a familiar interface that does not ...
(Date:4/28/2017)... ... ... sleep affects much more than energy – it also has mental and physical benefits. According ... reaction time, which can increase the risk of having a car accident. , This ... NSF to help you sleep better and feel better:, , Turn ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly ... offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and ... These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor and ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... exposed to more adverse experiences than children in the general population. That’s because ... abuse, neglect or other family challenges. While no fault of their own, youth ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection ... improve drug safety and minimize the cost of development. In this webinar, sponsored ... using cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... 20, 2017   ZappRx, Inc ., a digital health ... process, today announced it closed $25 million in Series B ... firm based in Seattle that is ... . The Series B round included participation from SR ... and GV (formerly Google Ventures). As part of ...
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
Breaking Medicine Technology: